AXL and leukemia: This macrophage-specific AXL deletion not only prolonged survival in AML models, but also resulted in heightened activation of both T cells and NK cells, as characterized by increased production of pro-inflammatory cytokines (IL-12, TNF-α), effectively targeting and eradicating both naïve and treatment-resistant leukemia cells.